Dementia Rates PLUNGED in Study of 1,091,775 People

The speaker walks through the entire controversy. He first addresses the fear that lowering blood cholesterol could harm the cholesterol‑rich brain, clarifying that brain cholesterol is made locally and dietary/pharmacological lowering does not deplete it in a harmful way. He cites the 2003 case series of 60 suspected statin‑related memory issues, but then pivots to higher‑quality data: the PROSPER trial (42 months of pravastatin vs. placebo) found no cognitive decline, and a more recent 5‑year study of very low LDL achieved with statins plus PCSK9 inhibitors also showed no cognitive harm. Observational data from 55 studies and 7 million patients show a 14% overall dementia risk reduction, jumping to 63% for statin use >3 years. But because observational studies can be plagued by healthy‑user bias, he emphasizes the new Mendelian randomization study as a natural experiment — people with gene variants that mimic statins or ezetimibe from birth show massive risk reductions. He also notes that midlife LDL levels are the critical window, and the Lancet Commission now lists high LDL as a modifiable dementia risk factor. The practical message is clear: lowering LDL cholesterol is a high‑priority strategy that simultaneously reduces heart disease and dementia risk, and it should begin as early in life as possible.

The speaker explains that globally, about 20% of people have some hearing loss, and the prevalence increases with age. He presents striking data: participants with hearing loss tracked over 5 years had up to 2.4 times the risk of developing dementia, and for every 10‑decibel worsening, dementia risk rises by 16%. This dose‑response relationship strongly suggests causation. He then highlights the silver lining: a systematic review comparing hearing‑impaired individuals who used hearing aids to those who did not found that hearing aid users had a significantly lower risk of cognitive decline and dementia. The analogy he uses is that just as muscles atrophy without use, the brain withers without sensory stimulation. Treating hearing loss is therefore positioned as a simple but powerful intervention — one that often goes overlooked but can make a huge difference for long‑term brain health, with the implication that regular hearing checks should be part of standard preventive care.

The speaker parallels hearing loss with vision loss: both deprive the brain of the stimulation it needs to stay healthy. He references a major meta‑analysis of 14 longitudinal studies encompassing over 6 million adults who were cognitively normal at baseline. Over follow‑ups of up to 14.5 years, those with vision loss had a significantly higher risk of developing dementia — approximately 47% higher. He frames vision correction as another puzzle piece in protecting brain health and urges people to take vision issues seriously and fix them. Although he doesn’t break down whether certain types of vision loss (e.g., cataracts vs. refractive error) confer different risks, the message is straightforward: maintaining clear sensory input is a modifiable factor that likely reduces dementia risk.

The speaker highlights that depression is a hidden yet powerful dementia risk factor. He cites an analysis of seven studies that followed people over 10–14 years: those with depression had more than doubled dementia risk compared to their non‑depressed peers. Critically, this increased risk is present across adult ages but especially relevant in midlife, making midlife depression a strong predictor of later‑life dementia. However, the same body of research showed that individuals who treated their depression — with medication, therapy, or both — experienced a significantly lower risk of developing dementia, with an approximate 30% risk reduction relative to those who went untreated. He also notes that this ties into social isolation, as depression often leads to withdrawal. The takeaway is that treating depression is not just about improving mental health today; it is a critical step for protecting brain health over the long term, and he urges anyone dealing with depression (or who knows someone who is) to seek treatment.

The speaker draws a direct analogy: just as we need to use our muscles to keep them healthy, we must challenge our minds to keep our brains healthy and ward off dementia. He references a large study of over 107,000 individuals that demonstrated participants with high cognitive stimulation at work had a lower dementia risk than those with low stimulation. While he doesn’t detail the exact types of stimulation, the implication is that effortful mental activity — problem‑solving, learning new skills, reading, strategic games — provides a protective effect. The speaker lists this as one of the less obvious but most impactful interventions, alongside hearing and vision care, essentially framing mental exercise as a core pillar of a brain‑healthy lifestyle. He also notes that this is tightly linked to social and sensory engagement, which together form a protective cluster.

The speaker briefly reviews a large trial that investigated daily multivitamin/mineral supplementation over 2 years. Participants showed relative improvements in overall cognition and memory compared to placebo, and the effect size was translated into a tangible metric: equivalent to reducing brain aging by 2 years. This is presented as one of the few supplements with solid evidence for cognitive benefits. However, he is careful to differentiate between evidence and personal practice: he takes a multivitamin/mineral as part of his personal stack but emphasizes that his choice does not constitute a recommendation for everyone. The underlying message is that this is a simple, low‑cost intervention with some promise, but results are not miraculous and individual needs vary.

The speaker explains that creatine is well‑known for boosting exercise performance and muscle building, but its role in the brain is often overlooked. Our bodies produce creatine, and diet provides additional sources. The brain contains creatine and depends on it for rapid energy production to fuel critical processes like memory and thought. Recent research shows that oral creatine supplementation can increase brain creatine levels. The 2022 meta‑analysis summarizing randomized trials confirmed that creatine supplements improved memory performance versus placebo, and the benefit was particularly robust in older adults — a population most vulnerable to cognitive decline. He notes this is not a definitive Alzheimer’s prevention strategy, but it fits into a broader toolkit. He personally takes creatine as part of his supplement powder and frames it as a supplement that makes mechanistic sense and has supportive, though not conclusive, human data.

The speaker discusses the amino acid homocysteine as a risk factor for Alzheimer’s disease. A 2020 comprehensive review of Alzheimer’s risk factors identified high homocysteine as being strongly tied to the disease and went on to say that homocysteine‑lowering treatment appears to be the most promising intervention for Alzheimer’s prevention. TMG, a compound often used for exercise performance, is an effective methyl donor that lowers homocysteine levels. He presents TMG as a supplement that could theoretically reduce this risk factor, though he carefully states that this is not a guaranteed prevention method — it’s an area of promising research. He personally includes TMG in his daily supplement stack, alongside a multivitamin and creatine, and frames it as a speculative but mechanistically plausible addition. The speaker does not name a specific dose or brand for TMG alone, but ties it to his microvitamin plus powder.

The speaker explains how this design works: people born with gene variants that mimic cholesterol‑lowering drugs are essentially ‘on the medication’ from birth. By comparing them to those without the variant, researchers can see the effect of lifelong exposure in a way Randomized Controlled Trials (RCTs) miss because routine trials are too short to capture benefits that may take decades to appear. The new study examined three classes — statins, ezetimibe, and PCSK9 inhibitors — each lowering LDL via a different pathway. The magnitudes were striking: 76% risk reduction for the statin‑mimic group and 82% for the ezetimibe group. However, the most potent LDL‑lowering class, PCSK9 inhibitors, showed no consistent dementia protection across three different analyses (one hinted at protection, two showed none). This suggests that off‑target effects of statins (anti‑inflammatory, antioxidant) or the enteric pathway of ezetimibe may be the real drivers of neuroprotection, not simply having a low LDL number. The speaker frames this as a key reason to prioritize cholesterol management earlier in life — midlife LDL levels are what appear to matter — and the new data strengthens the case that long‑term, pathway‑specific lowering is highly protective.

The Mendelian randomization study compared three genetic mimics of cholesterol‑lowering medications. While statin and ezetimibe mimics showed huge risk reductions (76% and 82%), the PCSK9 inhibitor mimic showed at best an inconsistent signal — one analysis suggested protection, but two others found none. Because PCSK9 inhibitors are the most powerful at driving down LDL, this result implies that simply having very low LDL is not enough; the actual biological mechanism by which LDL is lowered (e.g., HMG‑CoA reductase inhibition vs. PCSK9 inhibition) may be what matters for the brain. The speaker notes that statins have anti‑inflammatory and antioxidant effects that could confer additional protection beyond LDL lowering, and ezetimibe operates via a different pathway (intestinal cholesterol absorption). This surprising finding raises the bar for future drug development: a dementia‑preventive cholesterol agent may need to target the right pathway, not just the LDL number. The speaker positions this as an area where more research is urgently needed and admits that clinicians still have much to learn.

The speaker opens with the theoretical worry: the brain contains 20% of the body’s cholesterol and makes its own supply, so lowering blood cholesterol via diet should be safe, but statins might cross the blood‑brain barrier. Early case reports (2003, 60 cases) described suspected statin‑induced memory loss that improved on stopping, but RCTs like PROSPER (4‑year pravastatin vs. placebo) and a recent 5‑year study of statins plus PCSK9 inhibitors showed no cognitive decline. Meanwhile, observational meta‑analyses pointed to up to 63% lower dementia risk with long‑term statins. The new Mendelian randomization study now adds evidence that lifelong cholesterol lowering via statin or ezetimibe pathways is profoundly protective. It is in this context that the speaker says the Lancet Standing Commission has listed high LDL as a key modifiable dementia risk factor, making cholesterol management a “kill two birds with one stone” intervention — good for the heart and the brain. The take‑home is that tackling high LDL, ideally from midlife onward, should be a priority for anyone concerned about dementia, and the evidence is now compelling enough for official endorsement.